20273 results for «»
20273 results
PCR's Got Talent Round 1 - Session 2
20 May 2025 – From EuroPCR 2025
Join the dynamic PCR's Got Talent Round 1 - Session 2 featuring cutting-edge research and innovations in interventional cardiology. Highlights include complex CTO PCI strategies, valve comparisons in TAVI for small annuli, PFO closure outcomes, long-term PCI durability, CT-guided robotic PCI, pacemaker prediction post-TAVI, and much...
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
How to approach succesfully calcified bifurcation lesions?
20 May 2025 – From EuroPCR 2025
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario.
In this EuroPCR 2025 interview, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explain why this subset deserves dedicated attention. They highlight the critical role of intra-coronary...
How to successfully approach CTO interventions: a step-by-step approach
20 May 2025 – From EuroPCR 2025
Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.
The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...
What are the essential aspects of transcatheter LAA closure?
20 May 2025 – From EuroPCR 2025
Ole De Backer and Philippe Garot discuss the rapid evolution of transcatheter left atrial appendage (LAA) occlusion.
They begin by contrasting patient selection in Europe and the US, where approaches diverge significantly: in Europe, very high bleeding risk remains the main criterion, while in the US, LAA...
Coronary Interventions: EuroPCR 2025 highlights
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Rasha Al-Lamee, Nieves Gonzalo, and Thomas Cuisset highlighted key advances in coronary interventions, with a strong emphasis on managing complex cases—particularly calcified lesions.
Throughout the Course, LIVE cases and expert hotlines showcased dedicated devices and evolving strategies designed specifically for these challenging lesions. Advanced...
How to implement the diagnosis of INOCA in everyday practice?
20 May 2025 – From EuroPCR 2025
In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these...
Structural and Valvular Interventions: EuroPCR 2025 highlights
22 May 2025 – From EuroPCR 2025
Christopher Cook, Nicolas Dumonteil, and Bernard Prendergast share their top EuroPCR 2025 highlights in structural heart interventions. Challenging cases like re-do TAVI, coronary re-access difficulties, and leaflet modification took center stage in case-based and LIVE sessions. Cutting-edge research was featured too, including a meta-analysis combining the...
How to tailor transcatheter mitral therapies in 2025? A new era
20 May 2025 – From EuroPCR 2025
In this discussion from EuroPCR 2025, Mayra Guerrero, Thomas Modine, and Philipp Lurz explore the evolving landscape of mitral valve treatment.
While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn't suit every patient. Alternatives like transcatheter mitral valve replacement (TMVR), annuloplasty, and NeoChord implantation...
FAITAVI - Major Late-Breaking Trial from EuroPCR 2025
22 May 2025 – From EuroPCR 2025
Presented at EuroPCR 2025, the FAITAVI trial brings new insights into the management of coronary artery disease in patients undergoing TAVI.
In this PCR Perspectives video, Stephan Windecker and Flavio Ribichini explore how the trial—the first of its kind—compared angiography-guided versus FFR-guided strategies for intermediate coronary lesions....
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Martine Gilard, Antonio Mangieri, and Marco Barbanti explore the strategy for handling coronary artery disease in patients undergoing TAVI. Is coronary angiography always required beforehand? Should PCI be performed in all cases—and if so, when? This exchange offers key insights to help guide your decisions on...
What are the fundamentals of an upfront two-stent strategy for bifurcation PCI?
21 May 2025 – From EuroPCR 2025
Nicola Ryan explores the fundamentals of an upfront two-stent strategy in bifurcation PCI with Dejan Milasinovic. When the side branch shows significant, high-grade stenosis or extensive disease, direct treatment—via POBA, DCB, or a second stent—may be preferred. Anatomy guides the decision between provisional and two-stent strategies,...
Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation
20 May 2025 – From EuroPCR 2025
Join Michael Mullen, Federico De Marco, and Philipp Lurz as they discuss the latest breakthroughs in the treatment of mitral and tricuspid regurgitation at EuroPCR 2025. In this roundtable session, they delve into both repair and replacement techniques, offering insights into new systems and their impact...
How to efficiently and safely manage calcified left main disease?
21 May 2025 – From EuroPCR 2025
Nicola Ryan and Flavio Ribichini explore the complexities of calcified left main stem disease, emphasizing the critical role of intracoronary imaging in improving patient outcomes. They discuss the practical use of mechanical circulatory support and debate stenting strategies, offering expert insights on when single or dual...
How to manage treatment dilemmas in STEMI patients with multivessel disease?
20 May 2025 – From EuroPCR 2025
Managing STEMI patients with multivessel disease is a complex challenge evolving rapidly thanks to new clinical evidence. Angela Mcinerney, Natalia Pinilla, and Matthias Götberg explore how findings from the COMPLETE trial and its intracoronary imaging substudy are reshaping treatment strategies.
Their discussion highlights the role of intracoronary...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
What is the latest in DCB practice?
21 May 2025 – From EuroPCR 2025
Robert Byrne and Bruno Scheller explore the current role of drug-coated balloon (DCB) angioplasty nearly two decades after its initial clinical use. This discussion covers when and how to apply DCB angioplasty effectively in everyday practice, focusing on lesion preparation for de novo coronary disease and...
Preventing distal particles embolization after DCB angioplasty
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Aloke Finn and Antonio Colombo share their insights on a specific and often overlooked complication of drug-coated balloon (DCB) angioplasty: particulate embolization.
They begin by clarifying the distinction between this phenomenon and traditional distal embolization, explaining that particulate embolization is iatrogenic and device-related—it is...
Vulnerable plaque PCI after PREVENT
22 May 2025 – From EuroPCR 2025
This interview with Michael Haude and Thomas Cuisset explores findings from the PREVENT trial, which included over 1,600 patients with vulnerable, physiologically non-significant plaques identified by IVUS.
Patients were randomised to optimal medical therapy (OMT) alone or OMT plus preventive PCI. While the composite endpoint favoured the PCI...
